Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. JYNT
JYNT logo

JYNT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Joint Corp (JYNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.140
1 Day change
0.66%
52 Week Range
13.470
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Joint Corp (JYNT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown significant financial improvement in its latest quarter and has long-term growth potential, the lack of immediate positive trading signals, neutral insider and hedge fund activity, and underwhelming management guidance post-refranchising suggest waiting for stronger entry points or clearer catalysts.

Technical Analysis

The MACD is positive and contracting, RSI is neutral at 58.685, and moving averages are converging. The stock is trading near its pivot level of 8.724, with resistance at 9.075 and support at 8.373. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • The partnership with Miller Subaru could drive patient traffic and support market expansion. Financials show significant YoY growth in net income (5510.51%) and gross margin (up 3.42%).

Neutral/Negative Catalysts

  • Management's post-refranchising pro forma model is underwhelming, according to analysts. No significant insider or hedge fund trading activity. Stock trend analysis suggests limited short-term upside.

Financial Performance

In Q4 2025, revenue increased by 3.08% YoY, net income surged by 5510.51% YoY, EPS remained flat at 0.07 YoY, and gross margin improved to 78.55%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital lowered the price target from $14 to $12 but maintained a Buy rating, citing long-term upside despite underwhelming management guidance.

Wall Street analysts forecast JYNT stock price to rise
5 Analyst Rating
Wall Street analysts forecast JYNT stock price to rise
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 9.080
sliders
Low
9
Averages
11.33
High
14
Current: 9.080
sliders
Low
9
Averages
11.33
High
14
Roth Capital
Buy
downgrade
$14 -> $12
AI Analysis
2026-03-13
Reason
Roth Capital
Price Target
$14 -> $12
AI Analysis
2026-03-13
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Joint Corp. to $12 from $14 and keeps a Buy rating on the shares. The company's Q4 results exceeded estimates while its 2026 guidance largely mirrors the firm's model, the analyst tells investors in a research note. Roth adds, however, that the management's post-refranchising pro forma model is "underwhelming", even though it continues to see significant long-term upside.
B. Riley
B. Riley
Buy -> Neutral
downgrade
$18 -> $9
2025-11-07
Reason
B. Riley
B. Riley
Price Target
$18 -> $9
2025-11-07
downgrade
Buy -> Neutral
Reason
B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for JYNT
Unlock Now

People Also Watch